Coste-efectividad de la terapia fotodinámica en la degeneración macular asociada a la edad

  1. E. Muslera
  2. C. Natal
Journal:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Year of publication: 2006

Volume: 81

Issue: 4

Pages: 199-204

Type: Article

DOI: 10.4321/S0365-66912006000400005 DIALNET GOOGLE SCHOLAR lock_openOpen access editor

More publications in: Archivos de la Sociedad Española de Oftalmologia

Abstract

Objective: The aim of this study was to estimate the public health service cost of visual acuity improvement or maintenance with photodynamic therapy in patients with age-related macular degeneration (ARMD). This illness is the most frequent cause of blindness in elderly patients in western countries. Methods: A cost-effectiveness analysis was carried out to compare photodynamic therapy versus no treatment. The analysis point of view was that of the health service. The improvement or maintenance of visual acuity and contrast sensitivity were considered efficacy results. Direct costs were estimated by means of cost accountancy. Quality adjusted costs per visual acuity life year gained (QACVAG) were calculated through utility values from other studies. Results: The cost per year of maintenance of visual acuity in a two-year period was 36,530 € for women and 34,804 € for men. If this cost was estimated for life expectancy in Asturias, it would be reduced to 4,298 € for women and 5,354 € for men. If costs of the QACVAG, in a two-year period, were considered, photodynamic therapy would cost 66,931 € for women and 70,249 € for men. Conclusion: This cost-effectiveness analysis allows decisions to be made about public financing. Some research in our country suggests that public health financing should be provided for interventions whose cost-effectiveness is less than 30,000 € of CVAQA. The treatment evaluated here far exceeds this value. It is recommended that the use of more restrictive patient selection, incorporating diagnostic criteria and patient autonomy indicators, could improve the results of this intervention.

Bibliographic References

  • Congdon, N, O'Colmain, B, Klaver, CC, Klein, R, Munoz, B, Friedman, DS. (2004). Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 122. 477-485
  • Foran, S, Wang, JJ, Mitchell, P. (2003). Causes of visual impairment in two older population cross-sections: the Blue Mountains Eye Study. Ophthalmic Epidemiol. 10. 215-225
  • Farber, MD. (2003). National Registry for the Blind in Israel: estimation of prevalence and incidence rates and causes of blindness. Ophthalmic Epidemiol. 10. 267-277
  • Friedman, DS, O'Colmain, BJ, Munoz, B, Tomany, SC, McCarty, C, de Jong, PT. (2004). Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 122. 564-572
  • Jonasson, F, Arnarsson, A, Sasaki, H, Peto, T, Sasaki, K, Bird, AC. (2003). The prevalence of age-related maculopathy in Iceland: Reykjavik eye study. Arch Ophthalmol. 121. 379-385
  • Smith, W, Assink, J, Klein, R, Mitchell, P, Klaver, CC, Klein, BE. (2001). Risk factors for age-related macular degeneration: Pooled findings from three continents. Ophthalmology. 108. 697-704
  • Oneill, C, Jamison, J, McCulloch, D, Smith, D. (2001). Age-related macular degeneration: cost-of-illnes issues. Drugs Aging. 18. 233-241
  • (1999). A prospective, randomized, double-masked trial on radiation therapy for neovascular age-related macular degeneration (RAD study): Radiation Therapy for Age-related Macular Degeneration. Ophthalmology. 106. 2239-2247
  • Marcus, DM, Sheils, W, Johnson, MH, McIntosh, SB, Leibach, DB, Maguire, A. (2001). External beam irradiation of subfoveal choroidal neovascularization complicating age-related macular degeneration: one-year results of a prospective, double-masked, randomized clinical trial. Arch Ophthalmol. 119. 171-180
  • Salinas Alamán, A, García Layana, A, Juberías Sánchez, JR, Sánchez Tocino, H, Sádaba Echarri, LM, Moreno Montañes, J. (2002). Termoterapia transpupilar en neovascularización subretiniana oculta secundaria a degeneración macular asociada a la edad: Primeros Resultados. Arch Soc Esp Oftalmol. 77. 617-622
  • Oliva, G. (2002). Terapia fotodinámica en el tratamiento de la degeneración macular asociada a la edad. Agència d’Avaluació de Tecnologia y Recerca Mediques. Barcelona.
  • (2001). Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult no classic choroidal neovascularization--verteporfin in photodynamic therapy report 2. Am J Ophthalmol. 131. 541-560
  • Bressler, NM. (2001). Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap Report 2. Arch Ophthalmol. 119. 198-207
  • Rubin, GS, Bressler, NM. (2002). Effects of verteporfin therapy on contrast sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4. Retina. 22. 536-544
  • Brown, GC, Sharma, S, Brown, MM, Kistler, J. (2000). Utility values and age-related macular degeneration. Arch Ophthalmol. 118. 47-51
  • Aduriz-Lorenzo, P, Ceballos, M, Cienfuegos, S, Díaz-Varela, M, Natal-Ramos, C, Muslera-Canclini, E. (2003). Evaluación de un modelo de alta resolución para el tratamiento de la neovascularización subretiniana (NVSR) con verteporfín en el Principado de Asturias. Rev Calidad Asistencial. 18. 405-467
  • Sharma, S, Brown, GC, Brown, MM, Hollands, H, Shah, GK. (2001). The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology. 108. 2051-2059
  • Meads, C, Hyde, C. (2004). Photodynamic therapy with verteporfin is effective, but how big is its effect?: Results of a sytematic review. Br J Ophthalmol. 88. 212-217
  • Sacristan, JA, Oliva, J, Del Llano, J, Prieto, L, Pinto, JL. (2002). ¿Qué es una tecnología sanitaria eficiente en España?. Gac Sanit. 16. 334-343
  • Hopley, C, Salkeld, G, Mitchell, P. (2004). Cost utility of photodynamic therapy for predominantly classic neovascular age related macular degeneration. Br J Ophthalmol. 88. 982-987
  • Wang, JJ, Foran, S, Smith, W, Mitchell, P. (2003). Risk of age-related macular degeneration in eyes with macular drusen or hyperpigmentation: The Blue Mountains Eye Study cohort. Arch Ophthalmol. 121. 658-663
Data source: Dialnet